11.08.2014 23:09:38
|
Halozyme Therapeutics Q2 Loss Narrows - Quick Facts
(RTTNews) - Halozyme Therapeutics, Inc. (HALO) posted fourth-quarter net loss of $16.3 million or $0.13 per share, narrower than $22.9 million or $0.20 per share in the year-ago period.
On average, eight analysts polled by Thomson Reuters expected the company to report a loss of $0.14 per share. Analysts' estimates typically exclude special items.
Total revenues for the latest second quarter rose to $18.39 million from $14.45 million in the comparable quarter last year, while seven analysts had consensus revenue estimate of $13.71 million for the quarter.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Halozyme Therapeutics Inc.mehr Nachrichten
30.10.24 |
Ausblick: Halozyme Therapeutics öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Halozyme Therapeutics Inc.mehr Analysen
15.11.24 | Halozyme Therapeutics Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
Halozyme Therapeutics Inc. | 55,22 | 1,28% |
|